Published in Osteoporos Int on July 20, 2007
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med (2013) 2.06
Appropriate osteoporosis treatment by family physicians in response to FRAX vs CAROC reporting: results from a randomized controlled trial. J Clin Densitom (2013) 2.05
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations. J Midlife Health (2013) 1.47
Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int (2010) 1.46
The burden of illness of osteoporosis in Canada. Osteoporos Int (2012) 1.34
A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving. Osteoporos Int (2011) 1.34
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int (2011) 1.02
Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc (2012) 0.95
A systematic review of osteoporosis health beliefs in adult men and women. J Osteoporos (2011) 0.94
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93
Algorithms can be used to identify fragility fracture cases in physician-claims databases. Osteoporos Int (2011) 0.93
Institutionalization following incident non-traumatic fractures in community-dwelling men and women. Osteoporos Int (2011) 0.90
The contributions of First Nations ethnicity, income, and delays in surgery on mortality post-fracture: a population-based analysis. Osteoporos Int (2012) 0.90
Opportunistic screening for osteoporosis on routine computed tomography? An external validation study. Eur Radiol (2015) 0.89
Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int (2009) 0.87
Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int (2010) 0.87
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int (2011) 0.83
Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int (2010) 0.83
The burden of illness of osteoporosis in Canadian men. J Bone Miner Res (2012) 0.82
Identification and treatment of osteoporosis among elderly patients with hip fractures. Clinics (Sao Paulo) (2009) 0.82
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res (2013) 0.82
Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatr (2016) 0.80
A review of patient-centred post-fracture interventions in the context of theories of health behaviour change. Osteoporos Int (2011) 0.78
Agreement between physicians' and nurses' clinical decisions for the management of the fracture liaison service (4iFLS): the Lucky Bone™ program. Osteoporos Int (2015) 0.78
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice. Int J Womens Health (2016) 0.77
Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort study. BMC Musculoskelet Disord (2014) 0.77
A knowledge translation tool improved osteoporosis disease management in primary care: an interrupted time series analysis. Implement Sci (2014) 0.77
Evaluation of a clinical decision support tool for osteoporosis disease management: protocol for an interrupted time series design. Implement Sci (2011) 0.76
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women. J Bone Miner Metab (2013) 0.76
The impact of a standardized order set for the management of non-hip fragility fractures in a Fracture Liaison Service. Osteoporos Int (2016) 0.76
The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial. Osteoporos Int (2011) 0.75
A practical approach to osteoporosis management in the geriatric population. Can Geriatr J (2015) 0.75
Effects of water-based exercise on bone health of middle-aged and older adults: a systematic review and meta-analysis. Open Access J Sports Med (2017) 0.75
Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspective. J Am Assoc Nurse Pract (2014) 0.75
Dioxin-like compounds and bone quality in Cree women of Eastern James Bay (Canada): a cross-sectional study. Environ Health (2013) 0.75
The NYU Osteoporosis Model of Care Experience. Geriatr Orthop Surg Rehabil (2015) 0.75
A critical review of brand and generic alendronate for the treatment of osteoporosis. Springerplus (2013) 0.75
Prevalence of Osteoporosis and Effectiveness of Screening Test Using Ultrasound Bone Densitometry and Education in a Community-Dwelling Population. J Korean Med Sci (2017) 0.75
Exploring the Nurse Practitioner Role in Managing Fractures in Long-Term Care. Clin Nurs Res (2015) 0.75
Incidence of and factors for self-reported fragility fractures among middle-aged and elderly women in rural Korea: an 11-year follow-up study. J Prev Med Public Health (2014) 0.75
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med (1991) 5.83
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med (2001) 2.36
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Predictors for falls and fractures in the Longitudinal Aging Study Amsterdam. J Bone Miner Res (1998) 1.86
Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ (2000) 1.71
Osteoporosis in women 45 years and over related to subsequent fractures. Public Health Rep (1969) 1.68
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res (1998) 1.65
Epidemiology and predictors of fractures associated with osteoporosis. Am J Med (1997) 1.51
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Epidemiology of osteoporotic pelvic fractures in elderly people in Finland: sharp increase in 1970-1997 and alarming projections for the new millennium. Osteoporos Int (2000) 1.22
Contribution of weather to the seasonality of distal forearm fractures: a population-based study in Rochester, Minnesota. Osteoporos Int (1999) 0.98
Individuals who sustain nonosteoporotic fractures continue to also sustain fragility fractures. Calcif Tissue Int (1993) 0.94
Site-specific bone measurements in patients with ankle fracture. Osteoporos Int (2002) 0.79
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
The current and future market for veterinarians and veterinary medical services in the United States. J Am Vet Med Assoc (1999) 9.90
Finding protein similarities with nucleotide sequence databases. Methods Enzymol (1990) 6.63
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem (1996) 3.26
Institutional objectives for medical education that relates to the community. Can Med Assoc J (1984) 3.19
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA (2001) 2.70
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature (1985) 2.15
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res (1998) 2.12
Selective inactivation of the transacylase components of the 2-oxo acid dehydrogenase multienzyme complexes of Escherichia coli. Biochem J (1976) 2.10
A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res (1980) 1.89
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc (1999) 1.58
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J (1988) 1.57
Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium. Mutat Res (1976) 1.51
Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Regul Toxicol Pharmacol (1998) 1.51
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A (1986) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature (1982) 1.45
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Transaxillary pleurectomy for treatment of spontaneous pneumothorax. Ann Thorac Surg (1980) 1.41
Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology (1988) 1.41
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A (1988) 1.41
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc Natl Acad Sci U S A (1985) 1.39
On the carcinogenicity of cadmium by the oral route. Regul Toxicol Pharmacol (1992) 1.39
Dilemmas in caries diagnosis. J Am Dent Assoc (1993) 1.39
Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women. Osteoporos Int (2002) 1.39
Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. J Biol Chem (1980) 1.37
A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus. J Immunol Methods (1977) 1.36
Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int (2009) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
The burden of illness of osteoporosis in Canada. Osteoporos Int (2012) 1.34
Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg (1985) 1.32
Fast and robust optic disc detection using pyramidal decomposition and Hausdorff-based template matching. IEEE Trans Med Imaging (2001) 1.32
Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics (1997) 1.31
Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol (1981) 1.27
Hsc70-binding peptides selected from a phage display peptide library that resemble organellar targeting sequences. J Biol Chem (1995) 1.27
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem (1997) 1.26
Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes (1995) 1.25
Mutagenicity of plant flavonols in the Salmonella/mammalian microsome test: activation of flavonol glycosides by mixed glycosidases from rat cecal bacteria and other sources. Mutat Res (1979) 1.24
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Indirect 125I-labeled protein A assay for monoclonal antibodies to cell surface antigens. J Immunol Methods (1979) 1.20
A highly sensitive method for amino-acid analysis by a double-isotope-labelling technique using dansyl chloride. Eur J Biochem (1973) 1.18
Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol (1999) 1.16
An amino acid sequence in the active site of lipoamide dehydrogenase from the 2-oxoglutarate dehydrogenase complex of E. coli (Crookes strain). FEBS Lett (1972) 1.16
Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res (2003) 1.16
Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3. Nature (1983) 1.16
Incidence of breast-feeding in a low socioeconomic group of mothers in the United States: ethnic patterns. Pediatrics (1984) 1.15
Respiration of Lactobacillus casei. Can J Microbiol (1968) 1.14
Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology (1997) 1.14
Clinical features and motives among 42 artifactual illness patients. Br J Med Psychol (1983) 1.12
Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet (2001) 1.12
Social support, social influence, ethnicity and the breastfeeding decision. Soc Sci Med (1983) 1.12
Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int (2008) 1.11
Unique and common tumor-specific transplantation antigens of chemically induced mouse sarcomas. Int J Cancer (1978) 1.10
Nuchal cord as a cause of neonatal anemia. Am J Dis Child (1985) 1.10
Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry (2001) 1.08
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med (1999) 1.08
Peak bone mineral accrual and age at menarche in adolescent girls: a 6-year longitudinal study. J Pediatr (1998) 1.07
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone (2010) 1.07
Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol (1998) 1.06
Mutagenicity of anthraquinone and benzanthrone derivatives in the Salmonella/microsome test: activation of anthraquinone glycosides by enzymic extracts of rat cecal bacteria. Mutat Res (1979) 1.06
Reduction of polymeric azo and nitro dyes by intestinal bacteria. Appl Environ Microbiol (1981) 1.05
A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry (2009) 1.04
Gymnastic training and bone density in pre-adolescent females. Med Sci Sports Exerc (1997) 1.04
Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J Neurol Neurosurg Psychiatry (2005) 1.03
Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int (2011) 1.02
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int (2010) 1.01
Affinity labeling of a previously undetected essential lysyl residue in class I fructose bisphosphate aldolase. J Biol Chem (1976) 1.01
Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum (2000) 1.01
[3H]gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur J Pharmacol (1993) 1.00
Creatine supplementation combined with resistance training in older men. Med Sci Sports Exerc (2001) 1.00
Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res (1998) 1.00
Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A (1988) 0.99
Studies of a high molecular weight human melanoma-associated antigen. J Immunol (1983) 0.99
The Nance-Horan syndrome of dental anomalies, congenital cataracts, microphthalmia, and anteverted pinna: case report. Pediatr Dent (1985) 0.98
Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science (1978) 0.98
Frameshift mutagenicity of certain naturally occurring phenolic compounds in the 'Salmonella/microsome' test: activation of anthraquinone and flavonol glycosides by gut bacterial enzymes [proceedings]. Biochem Soc Trans (1977) 0.97
Susceptibility of the cell walls of some yeasts to lysis by enzymes of Helix pomatia. Can J Microbiol (1971) 0.97
Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release. Biochem Biophys Res Commun (1977) 0.96
Low-level arsenite activates the transcription of genes involved in adipose differentiation. Cell Biol Toxicol (2004) 0.95